Form 4: Liquidia CMO Sells Over 71K Shares in Planned Transaction
Insider Transaction Report
Liquidia Corp's Chief Medical Officer, Rajeev Saggar, sold 71,381 shares of common stock for $27 per share in a pre-arranged transaction.
Summary
- Chief Medical Officer Rajeev Saggar sold a total of 71,381 shares of Liquidia Corp common stock.
- The sales occurred on November 5, 2025, with each share transacting at a price of $27.
- The aggregate value of the shares sold amounted to approximately $1,927,287.
- These transactions were executed under a Rule 10b5-1 pre-arranged trading plan.
- Following these sales, Dr. Saggar beneficially owns 176,549 shares of common stock.
- Beneficial ownership includes 26,041 unvested restricted stock units (RSUs) from a January 11, 2023 grant, 31,777 unvested RSUs from a January 11, 2024 grant, and 71,780 unvested RSUs from a January 11, 2025 grant.
- Beneficial ownership also includes 2,221 shares of common stock acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The transaction is a pre-scheduled sale under a Rule 10b5-1 plan, which typically indicates a neutral event not driven by new material information. It reflects personal financial planning rather than a change in company fundamentals.
Future Outlook
No specific future outlook or guidance is provided in this insider transaction report.
Industry Context
This filing reports an individual insider transaction and does not provide broader industry context or trends.
Related Party Transactions
- Sale of 71,381 shares of common stock by Chief Medical Officer Rajeev Saggar.
Stakeholder Impact
- Shareholders may observe the insider selling, but the pre-arranged nature of the Rule 10b5-1 plan generally mitigates concerns about immediate negative implications for the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 01/11/2023 | Grant date for 83,333 restricted stock units to Reporting Person. |
| 01/11/2024 | Grant date for 56,492 restricted stock units to Reporting Person. |
| 01/11/2025 | Grant date for 71,780 restricted stock units to Reporting Person. |
| 11/05/2025 | Date of common stock transactions (sales). |
| 11/07/2025 | Signature date of the Form 4 filing. |
Recommendation
holdThe filing reports a pre-scheduled insider stock sale under a Rule 10b5-1 plan, which is a routine event for personal financial management and not typically indicative of a change in the company's fundamental outlook. Therefore, it does not provide new information to warrant a change from a 'hold' position based solely on this filing.
Keywords
Liquidia Corp, LQDA, Insider Trading, Form 4, Stock Sale, Chief Medical Officer, Rajeev Saggar, 10b5-1 Plan, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.